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Abstract Background: Transient lower esophageal sphincter relaxations (TLESRs)
have been identified as a primary cause of reflux events in patients with
gastroesophageal reflux disease (GERD). GABAB receptor agonists such as
lesogaberan (AZD3355) have been shown to inhibit TLESRs in healthy
subjects and patients with GERD, and, therefore, offer a novel therapeutic
add-on strategy to acid suppression for the management of GERD. As
lesogaberan is being developed as an add-on treatment for the management
of patients with GERDwho have a partial response to proton pump inhibitor
(PPI) therapy, it is important to rule out any clinically important pharm-
acokinetic drug-drug interaction between lesogaberan and PPIs.
Objective: To evaluate the effect of esomeprazole on the pharmacokinetics
and safety of lesogaberan and vice versa.
Study Design:This was an open-label, randomized, three-way crossover study.
The study was open to healthy adult male and female subjects. The study
subjects received treatment with, in random order, lesogaberan (150mg twice
daily [dose interval 12 hours]), esomeprazole (40mg once daily), and a com-
bination of both, during 7-day treatment periods.
Main Outcome: The presence or absence of pharmacokinetic interactions
between lesogaberan and esomeprazole was assessed by measuring the
steady-state area under the plasma concentration-time curves during the
dosing interval (AUCt) and the maximum observed plasma concentration
(Cmax) for lesogaberan and esomeprazole.
Results: Thirty male subjects (mean age 23.2 years, 97% Caucasian) were
randomized to treatment and 28 subjects completed the study (one subject
was lost to follow-up, and one subject discontinued due to an adverse event).
The 95% confidence intervals of the geometric mean ratios for AUCt and
Cmax of lesogaberan and esomeprazole administered alone and concomitantly
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were within the recognized boundaries of bioequivalence (0.8–1.25). No new
safety concerns were raised during this study. The number of patients with
adverse events during treatment with lesogaberan alone (n = 17) and con-
comitantly with esomeprazole (n = 18) were comparable but higher than
with esomeprazole alone (n = 10). Paresthesia (episodic, mild, and transient),
pharyngitis, and flatulence were the most frequently reported adverse events.
Conclusions: There was no observed pharmacokinetic interaction between
lesogaberan and esomeprazole when concomitantly administered to healthy
subjects, and concomitant therapy was well tolerated.
Trial registration number (clinicaltrials.gov): NCT00684190
Background
GABAB receptor agonists such as lesogaberan
(AZD3355) are known to inhibit transient lower
esophageal sphincter relaxations,[1] a primary cause
of reflux in patients with gastroesophageal reflux
disease (GERD).[2] Indeed, pharmacodynamic stud-
ies suggest possible therapeutic utility for lesoga-
beran in patients with persistent GERD symptoms
despite proton pump inhibitor (PPI) therapy.[3,4]
However, as lesogaberan was developed to be
used as an add-on medication for the treatment
of patients with a partial response to PPIs, it is
important to establish the lack of any clinically
important pharmacokinetic interaction between
these agents. Therefore, the aim of the present study
was to assess the steady-state pharmacokinetic
interaction between lesogaberan and esomepra-
zole when administered alone and concomitantly
to healthy subjects. Esomeprazole was chosen to
represent the PPIs as a class because it is widely
prescribed and mainly metabolized by cytochrome
P450 (CYP) 2C19 and CYP3A4,[5] as with ome-
prazole,[6,7] lansoprazole,[8,9] pantoprazole,[6,10] and
rabeprazole.[11,12]
Methods
This open-label, randomized, three-way cross-
over study[13] was conducted at a single Swedish
center, in accordance with ethical principles and
standards described in the Declaration of Helsinki
and the International Conference on Harmonisa-
tion (ICH)/Good Clinical Practice (GCP) guide-
lines. Written informed consent was obtained from
all participating subjects prior to the commence-
ment of the study.
Study Aims
The aims of this study were to assess the
pharmacokinetic interaction between lesogaberan
and esomeprazole at steady-state and vice versa
in healthy subjects via the assessment of the area
under the plasma concentration-time curve (AUC)
during the dosing interval (AUCt) [12 hours for
lesogaberan and 24 hours for esomeprazole] and
themaximumobserved plasma concentration (Cmax)
for lesogaberan and esomeprazole when admin-
istered alone and concomitantly. Additional study
evaluations included the assessment of AUC
from time zero until the last quantifiable con-
centration (AUCt), time to reach maximal plasma
concentration (tmax), terminal elimination half-
life (t½), and oral clearance (CL/F). The potential
for lesogaberan to induce CYP3A4 was measured
by the analysis of plasma 4-b-hydroxy-cholesterol
(4-bOH-cholesterol) concentrations. The safety
and tolerability of lesogaberan administered alone
and concomitantly with esomeprazole were also
assessed.
Study Population
Healthymale or female subjects aged 18–45 years
with a body mass index of 19–30 kg/m2 and a
body mass of 50–100 kg were eligible for inclu-
sion. Only surgically sterilized female subjects
were included in the study, as the reproductive
toxicology of lesogaberan is currently unknown.
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In order to ensure safety, subject exclusion criteria
included (i) a clinically significant illness within
2 weeks prior to the first dose of study medi-
cation(s); (ii) a history of allergy/hypersensitivity,
clinically significant orthostatic reactions/syncope,
or of cardiovascular, respiratory, renal, hepatic,
neurologic, mental, or gastrointestinal disease;
(iii) ongoing allergy/hypersensitivity; or (iv) any
concomitant condition/medication that could po-
tentially modify the pharmacokinetics of the study
drug(s).
Study Design and Treatments
The study flow is presented in figure 1. Fol-
lowing the pre-study screening visit, the study
consisted of three 7-day treatment periods sepa-
rated by washout periods of at least 13 days. On
day 1 of the first treatment period, subjects were
block randomized to random-order treatment with
the following three treatment regimens: (i) hard-
capsule modified-release formulation lesogaber-
an (150mg twice daily [dosing interval 12 hours])
dosed on the morning and afternoon of days 1–6
and once on the morning of day 7; (ii) esome-
prazole capsules (40mg once daily; formulated as
esomeprazole magnesium trihydrate 44.5mg) dosed
on the morning of days 1–7; or (iii) the two regi-
mens combined and dosed as described.
Study medications were administered with a
standardized volume (240mL) of water to fasted
subjects. Food was restricted from 11 pm on the
evening prior to administration of study med-
ication until 1 hour post-morning dose on days
1–6 or until 4 hours after the morning dose on
day 7; fluids were restricted from 1 hour pre-dose
until 1 hour post-morning dose on days 1–6 or
until 2 hours after the morning dose on day 7.
Standardized meals were provided 1 hour after
morning dosing on days 1–6 and 4 hours after
dosing on day 7. All study subjects were required
to stay at the study center overnight on day 6.
Additional study procedures included (i) daily
monitoring of adverse events via self-reporting
and direct questioning; (ii) orthostatic testing after
the standardized breakfast on day 1, pre-dose on
days 2 and 4, and 3 hours post-dose on day 7; and
(iii) a physical examination, supine blood pres-
sure and pulse measurements, and electrocardio-
graphy at the follow-up visit.
Sample Collection and Analysis
Plasma concentration-time profiles for leso-
gaberan and esomeprazole on day 7 were gen-
erated from blood samples (2mL) collected from
pre-dose until 12 hours post-dose: 0.5, 1.0, 1.5,
2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, 8.0, 10, and 12 hours
post-dose. Additional blood samples were taken
for the determination of pre-dose lesogaberan plas-
ma concentrations on days 4, 5, and 6 of the rel-
evant treatment periods. In order to evaluate the
potential for CYP3A4 induction, blood samples
were also collected pre-dose on days 1 and 7 for
the determination of 4-bOH-cholesterol plasma
concentrations in subjects receiving lesogaberan
alone.
Plasma samples were prepared by centrifugation
(relative centrifugal force, 1500 g) and immed-
iately frozen (-20C for lesogaberan and esome-
prazole; -70C for 4-bOH-cholesterol). Samples
were analyzed by an accredited laboratory (PRA
International, Assen, theNetherlands) using reverse-
phase liquid chromatography andmass spectrometry
methods for lesogaberan and 4-bOH-cholesterol,
and normal phase liquid chromatography with

























Fig. 1. Study design. R = randomization.
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ultra violet detection for esomeprazole. The lower
limits of quantification for lesogaberan and esome-
prazole were 0.03mmol/L and 0.025mmol/L.[14]
Statistical Analysis
A total of at least 30 subjects were randomized
to treatment to ensure at least 24 evaluable sub-
jects at the end of the study. The calculations to
determine the sample size were based on data
from previous studies.[14] For lesogaberan, it was
assumed that the within-subject standard devia-
tion (SD) of ln AUC and ln Cmax would be ap-
proximately 0.2, and that the within-subject SD
of the difference in ln AUC and ln Cmax would
then be approximately 0.28. With 24 evaluable
subjects, the probability that a 90% confidence
interval (CI) of the ratio would be no wider than
0.86, 1.16 was 80%. For esomeprazole, the ex-
pected within-subject SD of ln AUC and ln Cmax
was approximately 0.22 and 0.32. With 24 evalu-
able subjects, there was an 80% probability that
the 90%CIs of the geometric mean ratio for AUC
would be no wider than 0.85, 1.18, and that the
geometric mean ratio for Cmax would be no wider
than 0.78, 1.27.
Analysis Sets
The pharmacokinetic analysis set included all
subjects who received lesogaberan or esomeprazole
either alone or concomitantly, and had evaluable
pharmacokinetic data with no major protocol
deviations. The safety population was defined as
all subjects who received at least one dose of le-
sogaberan or esomeprazole either alone or con-
comitantly, and for whom post-dose data were
available.
Methods of Statistical Analysis
The pharmacokinetic analyses were performed
using standard non-compartmental methods and
WinNonlin Professional 4.1.b (or later) software
by Phase I Services, Quintiles AB,Uppsala, Sweden.
The log-transformed variables AUCt and Cmax
were analysed using a mixed model ANOVAwith
fixed effects for sequence, period, and treatment,
and a random effect for subject within sequence.
The evaluation of the effect of lesogaberan on the
pharmacokinetic variables of esomeprazole and
vice versawere performed by calculating 90% and
95% symmetrical t-distribution CIs for the mean
differences in log AUCt, log AUCt, and log Cmax
when lesogaberan and esomeprazole were ad-
ministered concomitantly versus alone. The CIs
were antilog transformed to generate CIs for the
ratios of geometric means and coefficients of
variation. Here, we report only the wider 95% CIs.
A similar transformation to calculate the ratio
of geometric means and corresponding 95% CIs
of 4-bOH-cholesterol plasma concentration fol-




A total of 30 healthy male subjects were ran-
domized to treatment according to the three-way
crossover design (table I). The three treatment
sequences were generally well balanced with respect
to baseline characteristics. Twenty-eight subjects
completed the study without protocol violation
and were included in the pharmacokinetic anal-
ysis set; one subject was lost to follow-up and one
subject was discontinued from treatment due to
an adverse event (fever).
Pharmacokinetic Variables
The steady-state plasma concentration-time
curves for lesogaberan and esomeprazole, admin-
istered alone and concomitantly, are presented in
figures 2 and 3. Analysis of trough plasma con-
centrations indicated that steady-state plasma con-
centrations for lesogaberan were attained prior to
Table I. Subject baseline characteristics (n= 30)
Characteristic Valuea Range
Age [y] 23.2 –3.9 18–35
Height [cm] 180.4 –6.9 166–195
Weight [kg] 75.4 –8.7 59–93
Body mass index [kg/m2] 23.3 –2.7 20–28
Ethnicity
White [n (%)] 29 (97)
Black or African American [n (%)] 1 (3)
a Values represented as mean –SD, unless stated otherwise.
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day 7. Although lag times were not recorded in
this study, visual inspection of the plasma con-
centration-time profile shows that the lag times of
lesogaberan and esomeprazole were not affected
when dosed together, relative to dosing alone.
The 95% CIs of the geometric mean ratios for
the AUCt, Cmax, and AUCt of lesogaberan after
concomitant administration with esomeprazole
versus lesogaberan alone were contained within
the accepted interval of bioequivalence (0.8–1.25,
table II). The corresponding variables for eso-
meprazole, administered concomitantly with le-
sogaberan versus esomeprazole alone, were also
contained within the accepted limits of bioequi-
valence (table II).
The geometric mean values of Cmax, t½, and
CL/F of lesogaberan and esomeprazole were
comparable when the drugs were administered
alone or concomitantly. The corresponding me-
dian tmax values for lesogaberan were compar-
able, although the median tmax of esomeprazole
when administered concomitantly with lesoga-
beran was slightly shorter compared with eso-
meprazole alone (table III). The mean and ranges
of tmax were comparable following administra-
tion alone (2.2 hours; range 1–4 hours) and con-
comitantly with lesogaberan (1.9 hours; range
1–4 hours).
During treatment with lesogaberan alone, the
geometric mean concentration of 4-bOH-cholesterol
was slightly reduced from pre-dose on day 1
(48.4nmol/L) to pre-dose onday 7 (44.0nmol/L); the
geometric mean ratio was 0.91 (95% CI 0.88, 0.94).
Safety and Tolerability
There were no deaths or serious adverse events
during the course of the study. One subject was dis-
continued from treatment while receiving lesoga-
beran concomitantly with esomeprazole due to fever
that was considered to be related to a viral infection.
A total of 119 adverse events were reported by
27 of the 30 subjects throughout the study. The
majority were either of mild or moderate in-
tensity (106 and 10 events). Three adverse events
that were graded as severe were reported (vaso-
vagal syncope, forearm injury [bicycle accident],
and myalgia). The event coded as vasovagal syn-
cope without fainting occurred during a blood
draw while the subject was pre-dose in day 7 of
the esomeprazole alone treatment period. The
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Fig. 2. Mean steady-state plasma concentration-time curves of lesogaberan when administered alone (n = 29) and concomitantly with eso-
meprazole (n =28). Data are the combined arithmetic mean values +SD of the two following treatment groups: (i) lesogaberan 150mg twice
daily (bid) [dosed in the morning and afternoon] on days 1–6 and 150mg once daily (od) [dosed in the morning] on day 7; and (ii) lesogaberan
150mg bid on days 1–6 and 150mg od on day 7, administered concomitantly with esomeprazole 40mg od (dosed in the morning) on days 1–7.
Data are from day 7.
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treatment with lesogaberan alone (n = 17) was
comparable to that during combined administra-
tion with esomeprazole (n = 18), but higher than
with esomeprazole alone (n = 10). The events that
were reported by the greatest number of sub-
jects during active treatment were transient par-
esthesia, pharyngitis, and flatulence (table IV). In
all subjects with paresthesia (n = 5), episodes were
mild in severity.
On day 1 in subjects treated with lesogaberan
alone, orthostatic testing showed that the mean
increase in reflectory pulse from a supine to
standing position was higher at 1 hour post-dose
(increase in beats per minute [bpm] measured
after 1 and 3minutes of standing, 24.7 and 27.0 bpm)
than pre-dose (16.3 and 16.6 bpm). A similar ef-
fect was also observed in subjects who received
concomitant treatment with lesogaberan and eso-
meprazole: 22.0 and 23.1 bpm, respectively, ver-
sus 14.6 and 19.0 bpm, respectively. However,
this effect was not observed in either the lesoga-
beran alone or concomitant treatment groups at
pre-dose on day 7 or at the 3-hour post-dose as-
sessment on day 7, nor at any timepoint following
treatment with esomeprazole alone. A total of
seven subjects experienced orthostatic reactions
(defined as a drop in diastolic [>10mmHg] and/
or a systolic [>25mmHg] blood pressure at 1 or
3 minutes after moving from a supine to a stand-
ing position), mostly on day 7 and with even
distribution across treatment periods; only one
subject had symptoms (dizziness) at the same
time as an orthostatic reaction. Additional or-
thostatic tests revealed that one subject had
Table II. Geometric mean ratios and 95% CIs of lesogaberan and
esomeprazole area under the plasma concentration-time curve
(AUC) during the dosage interval at steady-state (AUCt), maximum
plasma concentration at steady-state (Cmax), and AUC from time
zero until the last quantifiable plasma concentration (AUCt) when
administered concomitantly vs each alone
Parameter Geometric mean ratio 95% CI
Lesogaberan
AUCt 0.92 0.84, 1.02
Cmax 0.90 0.80, 1.03
AUCt 0.92 0.84, 1.02
Esomeprazole
AUCt 0.97 0.89, 1.07
Cmax 1.04 0.93, 1.17
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Fig. 3. Mean steady-state plasma concentration-time curves of esomeprazole, alone (n= 29) and concomitantly with lesogaberan (n =28).
Data are the combined arithmetic mean values +SD of the two following treatment groups: (i) esomeprazole 40mg once daily (od) [dosed in the
morning] on days 1–7; and (ii) lesogaberan 150mg twice daily (dosed in the morning and afternoon) on days 1–6 and 150mg od (dosed in the
morning) on day 7, administered concomitantly with esomeprazole 40mg od in the morning on days 1–7. Data are from day 7.
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syncope (3 hours post-dose on day 7, esomeprazole
alone) and one subject had a vasovagal reaction
(same patient as described previously in this sec-
tion for vasovagal syncope) pre-dose on day 7,
esomeprazole alone. A further two subjects re-
ported dizziness (pre-dose on day 1, lesogaberan
alone; and pre-dose on day 2, concomitant treat-
ment with lesogaberan and esomeprazole).
There were no clinically relevant changes in
ECG results, laboratory tests, or physical exam-
ination findings during the study.
Discussion
This study investigated the pharmacokinetic
interaction between lesogaberan and the PPI
esomeprazole in healthy subjects (pharmaco-
kinetic interactions between the two drugs were
not expected). Overall, findings were consistent
with no relevant pharmacokinetic interaction
when the drugs were coadministered at doses of
150mg (dosing interval 12 hours) and 40mg once
daily. Furthermore, repeated coadministration
was well tolerated with no new safety concerns.
The choice of a crossover study design, the
selection of the chosen range for the 95% CI in-
tervals for bioequivalence, and the methods of
pharmacokinetic analysis are standard for phar-
macokinetic drug-drug interaction studies. It is
also standard in drug interaction studies to select
high enough doses to ensure that any possible
pharmacokinetic interactions are detected. For







Paresthesia 5 (17) 4 (14) 1 (3)
Pharyngitis 2 (7) 3 (10) 0 (0)
Flatulence 1 (3) 4 (14) 0 (0)
Diarrhea 3 (10) 1 (3) 0 (0)
Rhinitis 3 (10) 1 (3) 1 (3)
Dizziness 1 (3) 3 (10) 1 (3)
Headache 1 (3) 3 (10) 0 (0)
Abdominal pain 1 (3) 2 (7) 0 (0)
Nasopharyngitis 1 (3) 2 (7) 0 (0)
Myalgia 0 (0) 3 (10) 0 (0)
Excoriation 2 (7) 0 (0) 0 (0)
a Adverse events experienced by two or more subjects in any treatment group are displayed.
Table III. Summary of the secondary pharmacokinetic variables of lesogaberan and esomeprazole when administered alone and con-
comitantly
Parameter Lesogaberan Esomeprazole
alone (n= 29) + esomeprazole (n= 28) alone (n =29) + lesogaberan (n =28)
Cmax [mmol/L]a 4.66 (22.6) 4.23 (38.4) 3.80 (31.5) 3.99 (25.9)
AUCt [mmol.h/L]a 35.00 (20.1) 32.32 (32.8) 11.40 (34.4) 11.21 (40.5)
AUCt [mmol.h/L]a 35.02 (20.0) 32.33 (32.8) 11.25 (34.4) 11.05 (40.0)
tmax [h]
b 3.00 (1.60–4.00) 3.00 (2.00–5.00) 2.50 (1.00–4.00) 1.51 (1.00–4.02)
t½ [h]
a 6.21 (23.5) 6.59 (23.7) 1.42 (21.5) 1.40 (22.5)
CL/F [L/h]a 30.37 (20.1) 32.88 (32.9) 10.16 (34.4) 10.33 (40.5)
a Values are geometric means (coefficient of variation).
b Values are medians (range).
AUCs = area under the plasma concentration-time curve during the dosage interval (t) at steady-state; AUCt=area under the plasma
concentration-time curve from time zero until the last quantifiable plasma concentration; CL/F =oral clearance at steady-state;
Cmax = observed maximum plasma concentration at steady-state; t½= terminal elimination half-life; tmax = time to reach the maximum plasma
concentration.
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this reason, the maximal approved dose of eso-
meprazole (40mg) was utilized, while the dose of
lesogaberan (150mg; dosing interval 12 hours)
was selected because it was in the upper range
of the expected therapeutic dose with favorable
safety. Although this study could recruit both
healthy male and female subjects, the frequency
of healthy female subjects meeting the inclusion
criterion of being surgically sterilized and aged
18–45 years was low; consequently, only male
subjects were recruited. Although there have been
slight differences in the pharmacokinetic profile
of esomeprazole between male and female sub-
jects (greater systemic exposure in females), these
differences have been shown to be statistically
insignificant.[15]
Comparisons of the 95% CIs of the geometric
mean ratios of systemic exposure (AUCt and
Cmax) for lesogaberan and esomeprazole when
administered alone and concomitantly were
within the standard limits of bioequivalence.
Therefore, comparisons indicate that no pharma-
cokinetic interaction occurs following repeated
coadministration of lesogaberan and esomepra-
zole in healthy subjects.
However, the majority of the study volunteers
(>96%) were Caucasian and, as such, the gen-
eralizability of these results to other populations
where variable CYP genetic expression is more
important is limited. Although pharmacogenetic
data were not collected in this study, CYP2C19
polymorphism has been shown to have minimal
impact on the pharmacokinetics and pharmaco-
dynamics of esomeprazole in homozygous and
heterozygous CYP2C19 extensive metabolizers,[16]
and the pharmacokinetic parameters of esome-
prazole dosed alone in this study are similar to
those previously reported.[15] Furthermore, the
ratio and 95% CI of 4-bOH-cholesterol concen-
trations before and after treatment with lesoga-
beran indicated that lesogaberan does not induce
CYP3A4. This finding is congruent with pre-
clinical studies that show that HepaRG cell
CYP3A4, 1A2, 2B6, and 2C9 messenger RNA
levels are not increased following cellular in-
cubation with lesogaberan at concentrations of
up to 30 mmol/L.[14] Furthermore, additional
preclinical studies have shown that lesogaberan
does not inhibit CYP1A2, 2C9, 2C19, 2D6, or
3A4.[17]
Although esomeprazole is representative of other
PPIs in so far as its metabolism is via CYP3A4
and 2C19, the fractional dependence on these
enzymes for the metabolism of other PPIs and the
effects of genetic enzyme variability on the metab-
olism of other PPIs[16] imply that caution is required
when expanding these results to the potential in-
teraction between lesogaberan and other PPIs.
No new safety concerns were raised during
this study. The most common adverse events in
this study (transient paresthesia, pharyngitis, and
flatulence) corresponded to those reported in other
clinical studies with lesogaberan.[3,4] Furthermore,
the large number of adverse events occurring
during treatment with lesogaberan alone or con-
comitantly with esomeprazole may, in part, be
explained by the reporting of paresthesia as
multiple events when it occurred at the same time
but in different body parts. Although the ortho-
static effects that were observed in this study were
not of great medical significance in a population
of this age, these effects may have a greater impact
in elderly patients who may have hypertension.
Although this study was performed using
standard methods and analyses, there are some
limitations. These include a male and Caucasian
study population that limits the generalizability
of these findings to the wider public, and the lack
of pharmacodynamic data.
Conclusion
No pharmacokinetic interaction was seen be-
tween lesogaberan (150mg; dosing interval 12 hours)
and esomeprazole (40mg once daily) following re-
peated coadministration in healthy subjects. Fur-
thermore, repeated coadministration was well
tolerated. Therefore, lesogaberan may be used con-
comitantly in patients receiving esomeprazole,
without the risk of pharmacokinetic interaction.
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